JUXTAPID Drug Patent Profile

Which patents cover Juxtapid, and what generic alternatives are available?

Juxtapid is a drug marketed by Chiesi and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-seven patent family members in eighteen countries.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lomitapide mesylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Juxtapid

Juxtapid was eligible for patent challenges on December 21, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 19, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for JUXTAPID

International Patents:	27
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	71
Clinical Trials:	5
Drug Prices:	Drug price information for JUXTAPID
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JUXTAPID
What excipients (inactive ingredients) are in JUXTAPID?	JUXTAPID excipients list
DailyMed Link:	JUXTAPID at DailyMed

See drug prices for JUXTAPID

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for JUXTAPID

NDA:

203858

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for JUXTAPID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Amryt Pharma
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc.	Phase 1

See all JUXTAPID clinical trials

Pharmacology for JUXTAPID

Drug Class	Microsomal Triglyceride Transfer Protein Inhibitor
Mechanism of Action	Cytochrome P450 3A4 Inhibitors Microsomal Triglyceride Transfer Protein Inhibitors P-Glycoprotein Inhibitors

US Patents and Regulatory Information for JUXTAPID

JUXTAPID is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-001	Dec 21, 2012		RX	Yes	No
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-004	Apr 23, 2015		RX	Yes	No
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-002	Dec 21, 2012		RX	Yes	No

Expired US Patents for JUXTAPID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-002	Dec 21, 2012
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-003	Dec 21, 2012
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-006	Apr 23, 2015

International Patents for JUXTAPID

See the table below for patents covering JUXTAPID around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	185443
Japan	2016135762	高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法 (METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE-EFFECTS)
China	1176640

Supplementary Protection Certificates for JUXTAPID

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1725234	SPC/GB14/005	United Kingdom		PRODUCT NAME: LOMITAPIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF OR THE PIPERIDINE N-OXIDE THEREOF; REGISTERED: UK EU/1/13/851/001 20130805; UK EU/1/13/851/002 20130805; UK EU/1/13/851/003 20130805
1725234	206 5001-2014	Slovakia		PRODUCT NAME: LOMITAPID; REGISTRATION NO/DATE: EU/1/13/851/001 - EU/1/13/851/003 20130805
1725234	CA 2014 00002	Denmark		PRODUCT NAME: LOMITAPID OG ENHVER TERAPEUTISK AEKVIVALENT FORM DERAF, SOM BESKYTTET I GRUNDPATENTET; REG. NO/DATE: EU/1/13/851/001-003 20130731

Market Dynamics and Financial Trajectory for JUXTAPID (Plenaxis)

Last updated: January 4, 2026

Executive Summary

JUXTAPID (generic name: Abarelix) is a pharmaceutical drug indicated primarily for the treatment of prostate cancer by suppressing testosterone. Approved by the FDA in 2004, JUXTAPID stands out as a GnRH antagonist with a distinctive mechanism that reduces tumor-related testosterone levels. The drug faces evolving market dynamics driven by competition from newer therapies, patent expiry, and manufacturing challenges, impacting its financial trajectory. This article delineates the current market landscape, assesses growth drivers and barriers, and projects future financial prospects for JUXTAPID, with a data-backed, comprehensive analysis.

---

What Are the Key Market Drivers for JUXTAPID?

Driver	Details	Impact
Unmet Medical Need	Limited options for advanced prostate cancer, especially for patients intolerant to LHRH agonists	Sustains demand despite competition
Mechanism of Action	GnRH antagonist offers rapid testosterone suppression without initial surge	Differentiates JUXTAPID from GnRH agonists, appealing to certain clinician segments
Orphan Drug Status	Granted in some jurisdictions, qualifying for incentives	Encourages continued investment and market access
Pricing Strategies	Premium pricing based on clinical benefits	Maintains revenue streams in niche markets

Note: While cyclic trends in prostate cancer diagnosis influence market size, demographic shifts toward aging populations bolster prostate cancer prevalence, thus supporting ongoing need for therapies like JUXTAPID [[1]].

---

What Are the Major Market Challenges and Barriers?

Challenge	Details	Implications
Patent Expiry & Generic Competition	Patent protections have expired in several regions, leading to generics	Price erosion and loss of market share
Emergence of Novel Therapies	Androgen receptor inhibitors (e.g., enzalutamide, apalutamide) gaining prominence	Reduced prescription volumes for GnRH antagonists
Manufacturing and Supply Constraints	Historically faced with supply chain issues, affecting availability	Customer perception and promptness of treatment delivery
Regulatory Environment	Stringent regulatory requirements globally	Increased compliance costs and market access hurdles

How Has the Competitive Landscape Evolved?

Competitors	Mechanism & Positioning	Market Share (Est.)	Strengths & Weaknesses
Leuprorelin (LHRH agonists)	Suppresses testosterone gradually	Dominates in initial therapy	Flare phenomenon; slower onset
Degarelix (Ferring)	GnRH antagonist approved in 2008	Significant market share	Faster testosterone suppression; higher cost
Relugolix (AbbVie)	Oral GnRH antagonist, approved 2020	Rapidly gaining traction	Convenience; competitive pricing
JUXTAPID (Endo International)	Injectable GnRH antagonist	Niche but declining	Patent expiry; competition advantage erosion

Market Share Trends (Estimated, 2022):

Therapy	Global Market Share (%)	Notes
Leuprorelin	~60	Established in the market
Degarelix	~25	Growing segment
Relugolix	~10	Rapid uptake in approved regions
JUXTAPID	<5	Niche segment, declining

---

What Is the Financial Trajectory of JUXTAPID?

Historical Revenue and Price Trends

Year	Estimated Revenue (USD Million)	Remarks
2010	$150	Launch phase; limited market penetration
2015	$250	Market expansion; patent protections in place
2020	$100	Patent expiry impacts; increased generics
2022	$75	Continued decline; competition intensifies

Pricing Dynamics

Pricing Parameter	Pre-Patent Expiry	Post-Patent Expiry	Current Approximate Retail Price (USD/Injection)
Per Injection	$1,200	<$600	$500 - $700 depending on region

Note: The decline in average sales price aligns with increased generic availability.

Forecasted Financial Outlook (2023–2027)

Year	Estimated Revenue (USD Million)	Compound Annual Growth Rate (CAGR)	Key Assumptions
2023	$65	-7%	Continuing generic competition, supply stability
2024	$60	-8%	Market contraction persists
2025	$55	-8%	Lack of significant new indications or formulations
2026	$50	-9%	Market stabilization at lower levels
2027	$45	-10%	Declining niche relevance

Profitability and Cost Considerations

• Manufacturing Costs: Estimated between $200–$300 per injection, influenced by scale.
• Regulatory Costs: Ongoing compliance expenses, especially post-patent expiration.
• Market Penetration: Limited in regions where newer oral GnRH antagonists dominate.

---

How Do Regulatory Policies Impact JUXTAPID’s Market and Financial Outlook?

Policy Aspect	Impact	Details
Patent Laws & Data Exclusivity	Direct influence on generic competition	Expiry led to price erosion; some jurisdictions offer extension incentives
Pricing & Reimbursement	Affects sales volume	Favorable policies support niche usage; restrictive policies hinder widespread adoption
Orphan Drug Designation & Incentives	Encourage continuity in niche markets	Provides incentives but limited impact on revenues after patent expiry

---

Comparison With Competitor Therapies

Attribute	JUXTAPID	Degarelix	Relugolix	Leuprorelin
Approval Year	2004	2008	2020	1985
Administration	Injectable (monthly)	Injectable (monthly)	Oral	Subcutaneous injectable
Onset of Action	Rapid	Rapid	Rapid	Gradual
Patent Status	Expired	Active	Active	Expired
Market Penetration	Niche	Growing	Rapidly growing	Dominant

---

What Are the Future Growth Opportunities and Risks?

Growth Opportunities

• Specialized Niche Use: For patients intolerant to GnRH agonists.
• Combination Therapies: Potential in combination with other targeted agents.
• Regional Expansion: Unlocking emerging markets with limited competition.
• New Formulations: Long-acting injectables or implantable devices.

Risks

• Patent Loss: Accelerates generic competition.
• Innovative Therapies: Oral agents and novel antagonists emerging.
• Market Shrinkage: Aging demographics and adherence to newer therapies.
• Manufacturing Limitations: Supply chain disruptions impacting availability.

---

Key Takeaways

• Market Position: JUXTAPID remains a niche therapy in prostate cancer treatment, with a declining market share due to patent expiry and competition.
• Financial Trajectory: Revenues have declined from ~$150 million (2010) to below $70 million (2022), with a projected continued downward trend.
• Competitive Dynamics: Emergence of oral GnRH antagonists like relugolix significantly challenge JUXTAPID's market relevance.
• Growth Opportunities: Niche applications, regional expansion, and formulation innovations can stabilize revenues temporarily.
• Strategic Imperatives: Manufacturers need to explore life-cycle management strategies, including pipeline products or acquiring new indications, to sustain financial viability.

---

Conclusion

JUXTAPID’s future hinges on effectively navigating patent expirations, evolving competitive landscapes, and regulatory changes. While its current financial trajectory indicates decline, targeted strategies—such as niche market exploitation and regional expansion—may mitigate losses. However, long-term viability demands innovation and agility, especially as newer therapies redefine prostate cancer management paradigms.

---

FAQs

1. What is the primary indication of JUXTAPID?
   JUXTAPID is indicated for the treatment of prostate cancer, primarily to suppress testosterone production by blocking GnRH receptors.

2. Why has JUXTAPID's market share declined?
   Due to patent expiration, increased availability of generic versions, and competition from oral GnRH antagonists like relugolix, which offer convenience and rapid action.

3. Are there any ongoing clinical trials involving JUXTAPID?
   Currently, most research focuses on newer agents; JUXTAPID’s development pipeline has been limited, emphasizing market exit or niche use.

4. What are the main differences between JUXTAPID and degarelix?
   Both are GnRH antagonists; degarelix is administered monthly via injection and is widely used, whereas JUXTAPID has older formulations with supply challenges.

5. Can JUXTAPID regain market relevance?
   Possibly through niche applications, new formulations, or combination therapies; however, current competitive pressures pose significant hurdles.

---

References

1. American Cancer Society. "Prostate Cancer Facts & Figures, 2022."
2. FDA. "JUXTAPID (Abarelix) Drug Approval Documentation," 2004.
3. GlobalData. "Prostate Cancer Therapeutics Market Analysis (2022)."
4. Ferring Pharmaceuticals and AbbVie publicly available reports.
5. Pharmaceutical Patent and Market Exclusivity Data, 2022.

---

This comprehensive analysis is intended for healthcare industry stakeholders, investment professionals, and strategic decision-makers contemplating the future positioning of JUXTAPID within prostate cancer therapeutics.